立体定向放射外科时代美国脑转移放疗实践模式
该研究基于美国国家癌症数据库2010至2015年确诊时即伴脑转移的成人患者,分析立体定向放射外科(SRS)与全脑放疗(WBRT)的使用趋势及剂量分割模式。结果显示WBRT使用比例下降而SRS使用翻倍,放射抵抗组织学患者更倾向接受SRS,未接受化疗者更少接受SRS且更多接受短程WBRT。
要点
- 确诊时脑转移患者中,WBRT年使用比例从27.8%降至23.5%,SRS从8.7%升至17.9%。
- WBRT最常见分割为30 Gy/10次(56.8%),SRS为20 Gy/1次(13.0%)。
- 放射抵抗组织学、学术机构、高收入、化疗及较长出行距离与选择SRS独立相关。
核心结论
- 确诊时脑转移患者首选放疗中,WBRT使用(尤其超长程分割)下降而SRS使用翻倍。
- 放射抵抗组织学患者更可能接受SRS,未接受化疗者更少接受SRS且更可能接受短程WBRT。
研究设计与样本
- 基于美国国家癌症数据库的照护模式分析,纳入2010至2015年确诊癌症时伴脑转移且无既往恶性肿瘤的成人。
- 共4,087,967例首次终生癌症成人中,90,388例(2.2%)初诊时伴脑转移。
主要发现
- 90,388例脑转移患者中,11,486例(12.7%)首选SRS,24,262例(26.8%)首选WBRT。
- WBRT年使用比例从27.8%降至23.5%,SRS从8.7%升至17.9%。
- WBRT最常见分割为30 Gy/10次(56.8%),SRS为20 Gy/1次(13.0%)。
- 多因素分析中,2015年 vs 2010年(aOR=2.4)、放射抵抗(aOR=2.0)、学术机构(aOR=1.9)、最高收入四分位(aOR=1.6)、化疗(aOR=1.4)、出行距离>15 vs <5英里(aOR=1.4)与选择SRS vs WBRT显著相关。
- 线性回归显示超长程WBRT年降幅-22.4%/年(R²=0.97,P<.001),短程与标准WBRT无显著变化;未接受化疗者接受短程WBRT vs 标准WBRT的aOR=3.5。
关键数值与推荐
- SRS定义采用已发表阈值;短程WBRT为4-9次,标准WBRT为10-15次,超长程WBRT为>15次。
- 放射抵抗组织学定义为黑色素瘤、肾细胞癌、肉瘤或梭形细胞、或胃肠道原发。
临床怎么用
- 脑转移初诊患者选择放疗时,应结合组织学放射抵抗性、机构类型、收入、化疗状态及出行距离等因素个体化权衡SRS与WBRT。
- 未接受化疗(可能因体能状态差)的患者更可能接受短程WBRT,提示临床决策需综合评估全身治疗可行性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Utilization of stereotactic radiosurgery (SRS) for brain metastases (BM) has increased, prompting reassessment of whole brain radiation therapy (WBRT). A pattern of care analysis of SRS and WBRT dose-fractionations was performed in patients presenting with BM at the time of cancer diagnosis. METHODS AND MATERIALS: Adults with BM at cancer diagnosis between 2010 to 2015 and no prior malignancy were identified in the National Cancer Database. SRS was defined using published thresholds. Short (ShWBRT), standard (StWBRT), and extended (ExWBRT) dose-fractionations were defined as 4 to 9, 10 to 15, and >15 fractions. Radioresistant histology was defined as melanoma, renal cell carcinoma, sarcoma or spindle cell, or gastrointestinal primary. RESULTS: Of 4,087,967 adults with their first lifetime cancer, 90,388 (2.2%) had BM at initial diagnosis. Of these, 11,486 (12.7%) received SRS and 24,262 (26.8%) WBRT as first-course radiation therapy. The proportion of annual WBRT use decreased from 27.8% to 23.5% of newly diagnosed patients, and SRS increased from 8.7% to 17.9%. Common dose-fractionations were 30 Gy in 10 fractions (56.8%) for WBRT and 20 Gy in 1 fraction (13.0%) for SRS. On multivariate analysis, factors significantly associated with SRS versus WBRT included later year of diagnosis (2015 vs 2010, adjusted odds ratio [aOR] = 2.4), radioresistance (aOR = 2.0), academic facility (aOR = 1.9), highest income quartile (aOR = 1.6), chemotherapy administration (aOR = 1.4), and longer travel distance (>15 vs < 5 miles, aOR = 1.4). Linear regression revealed significant ExWBRT reductions (-22.4%/y, R2 = 0.97, P < .001) and no significant change for ShWBRT or StWBRT. Patients were significantly more likely to receive ShWBRT than StWBRT if not treated with chemotherapy (aOR = 3.5). CONCLUSIONS: Utilization of WBRT, particularly ExWBRT, decreased while SRS utilization doubled as the first radiation therapy course in patients with BM at diagnosis. Patients with radioresistant histologies were more likely to receive SRS. Those not receiving chemotherapy, potentially owing to poor performance status, were less likely to receive SRS and more likely to receive ShWBRT.
引用
- Barbour AB, Jacobs CD, Williamson H, et al. Radiation Therapy Practice Patterns for Brain Metastases in the United States in the Stereotactic Radiosurgery Era. Adv Radiat Oncol. 2019. PMID: 32051889. doi:10.1016/j.adro.2019.07.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。